Harmonization of intellectual property rights across the globe: Impact on India’s pharmaceutical exports

Supriya Bhandarkar
Additional contact information
Supriya Bhandarkar: Institute for Social and Economic Change

No 479, Working Papers from Institute for Social and Economic Change, Bangalore

Abstract: Critics of the global intellectual property rights (IPR) regime have argued that the harmonization of IPRs across the globe would lead to a fall in exports from a developing country like India by restricting the production and export of patented products. Methodologically, in a gravity model framework using the pseudo passion maximum likelihood (ppml) estimator and detailed product level data from 1991 to 2018, this paper assesses the impact of the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement on Indian pharmaceutical exports. The Ginarte and Park index serves to identify the impact. The results, contrary to assumption show that the strengthening of IPRs did not have a negative impact on the exports from India. Additionally, the results demonstrate that patent protection has not impacted Indian firms' exports, not due to innovation of new products but because of the adoption of other survival strategies such as the utilisation of the patent cliff and investing in incremental innovation.

Keywords: Intellectual; property; rights; Pharmaceutical; exports; India (search for similar items in EconPapers)
Date: 2020
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sch:wpaper:479

Access Statistics for this paper

More papers in Working Papers from Institute for Social and Economic Change, Bangalore Contact information at EDIRC.
Bibliographic data for series maintained by B B Chand ().